Sugi Predict

Sugi Predict / Targets / PDE6A

PDE6A

Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha · P16499 · PDE6A on Sugi Atlas →

13,682 patent compounds predicted against PDE6A, 11,023 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1970594 SCHEMBL1970594 0.69 9/20
SCHEMBL1970899 SCHEMBL1970899 0.69 9/20
SCHEMBL1970034 SCHEMBL1970034 0.68 9/20
SCHEMBL1970609 SCHEMBL1970609 0.76 8/20
SCHEMBL1971307 SCHEMBL1971307 0.73 8/20
SCHEMBL1971532 SCHEMBL1971532 0.73 8/20
SCHEMBL1969644 SCHEMBL1969644 0.69 8/20
SCHEMBL1979045 SCHEMBL1979045 0.68 8/20
SCHEMBL1970001 SCHEMBL1970001 0.64 8/20
SCHEMBL1972222 SCHEMBL1972222 0.64 8/20
SCHEMBL1969924 SCHEMBL1969924 0.61 8/20
SCHEMBL1974920 SCHEMBL1974920 0.61 8/20
SCHEMBL1973153 SCHEMBL1973153 0.72 7/20
SCHEMBL1970051 SCHEMBL1970051 0.71 7/20
SCHEMBL1970610 SCHEMBL1970610 0.71 7/20
SCHEMBL1970611 SCHEMBL1970611 0.71 7/20
SCHEMBL1971462 SCHEMBL1971462 0.71 7/20
SCHEMBL1970644 SCHEMBL1970644 0.70 7/20
SCHEMBL1970086 SCHEMBL1970086 0.68 7/20
SCHEMBL1976639 SCHEMBL1976639 0.65 7/20

Clinical trials — most relevant to PDE6A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
PDE6A Gene Therapy for Retinitis Pigmentosa PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Promising ROd-cone DYstrophy Gene therapY PHASE1/PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder PHASE2UNKNOWN
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Prospective Natural History Study of Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa nanUNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PDE6A binder may also engage these)

ProteinNameSimilarity
P16586 — 1.000 P16586 →
PDE6C Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' 1.000 landscape →
P23440 — 1.000 P23440 →
PDE6B Rod cGMP-specific 3',5'-cyclic phosphodiester 1.000 landscape →
Q28263 — 1.000 Q28263 →
P27664 — 1.000 P27664 →
P11541 — 0.999 P11541 →
P52731 — 0.998 P52731 →
Q91ZQ1 — 0.997 Q91ZQ1 →
Q1KKS3 — 0.995 Q1KKS3 →
P33726 — 0.995 P33726 →
P23439 — 0.995 P23439 →
O54735 — 0.994 O54735 →
P91119 — 0.993 P91119 →
P0C1Q2 — 0.992 P0C1Q2 →
Q8VID6 — 0.992 Q8VID6 →
Q28156 — 0.991 Q28156 →
B4K9L4 — 0.991 B4K9L4 →
B4LVU6 — 0.990 B4LVU6 →
B4HEM4 — 0.990 B4HEM4 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.988 landscape →
B4QZU1 — 0.988 B4QZU1 →
Q8QZV1 — 0.987 Q8QZV1 →
B4JXX2 — 0.987 B4JXX2 →
PDE11A Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A 0.987 landscape →
O77746 — 0.986 O77746 →
B3LVW5 — 0.985 B3LVW5 →
Q8CG03 — 0.985 Q8CG03 →
P14099 — 0.984 P14099 →
Q298P4 — 0.984 Q298P4 →